Blog

The Neuroendocrine Cancer Foundation (formerly LACNETS) attended the 2025 Annual European Neuroendocrine Tumor Society (ENETS)...

On Saturday, March 29th, 2025, the Neuroendocrine Cancer Foundation held a Regional Neuroendocrine Patient Educational Event in Tucson,...

Update (March 26, 2025): A New Treatment Option has been FDA approved for those living with NET.  The U.S FDA approved Cabozantinib for...

We are pleased to announce the evolution of the LACNETS organization by introducing our new name: Neuroendocrine Cancer Foundation . This...

LACNETS was busy learning from experts and making connections at the 2024 North American Neuroendocrine Tumor Society (NANETS) Annual...

On November 9th, LACNETS held its 2024 NET Cancer Day Symposium in Santa Monica, California, to recognize and celebrate World NET Cancer...

On Saturday, September 21, 2024, over 50 people living with or supporting those living with neuroendocrine cancer gathered for a Regional...

LACNETS participated in INCA’s 12th annual Global NET Patient Advocate Summit in Segovia, Spain with 24 other Patient Advocacy...

Neuroendocrine cancer patients often have a variety of available treatment options. Since this cancer behaves differently from other...

Exelixis Announces U.S. Food and Drug Administration (FDA) Accepted the Supplemental New Drug Application for Cabozantinib for Patients...